Consolidative nivolumab versus observation in unresectable stage III non-small cell lung cancer patients following neoadjuvant nivolumab plus chemotherapy and concurrent chemoradiotherapy (CA209-7AL): a randomized clinical trial.
The CA209-7AL phase 2 trial evaluated the efficacy and safety of consolidative nivolumab (NIVO) versus observation after...